Immunoconjugates and long circulating systems: Origins, current state of the art and future directions

Advanced Drug Delivery Reviews

Volumn 65, Issue 1, 2013, Pages 24-35

  Koshkaryev, Alexander ^a   Sawant, Rupa ^a   Deshpande, Madhura ^a   Torchilin, Vladimir ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Antibody; Immunoconjugation; Immunoliposomes; Immunomicelles; Long circulating systems; PEGylation

Indexed keywords

CURRENT STATUS; DRUG DELIVERY SYSTEM; ENZYMATIC ACTIVITIES; HEALTHY TISSUES; IMMUNOCONJUGATION; IMMUNOLIPOSOMES; IMMUNOMICELLES; INCREASED TEMPERATURE; LONG CIRCULATING; MICROENVIRONMENTS; PEGYLATION; SIDE EFFECT; STATE OF THE ART; STIMULUS-SENSITIVE; TARGET RECOGNITION; VASCULATURE;

ANTIBODIES; DRUG DELIVERY; DRUG INTERACTIONS; TISSUE;

ENZYME ACTIVITY;

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; DENILEUKIN DIFTITOX; DOXORUBICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOLIPOSOME; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB EMTANSINE;

B CELL LYMPHOMA; BINDING AFFINITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG TARGETING; HODGKIN DISEASE; HUMAN; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; MICELLE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; IMMUNOCONJUGATES; LIPOSOMES; MICELLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84873266331     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.08.009     Document Type: Review

References (224)

1. Reichert J.M. Antibody-based therapeutics to watch in 2011. MAbs 2011, 3:76-99.
2. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195:11-20.
3. Torchilin V.P. Affinity liposomes in vivo: factors influencing target accumulation. J. Mol. Recognit. 1996, 9:335-346.
4. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63:131-135.
5. Torchilin V.P. Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. 2010, 3-53.
6. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 2009, 71:431-444.
7. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
8. Reichert J.M., Rosensweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
9. Boulianne G.L., Hozumi N., Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 1984, 312:643-646.
10. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6851-6855.
11. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
12. Laffly E., Sodoyer R. Monoclonal and recombinant antibodies, 30 years after. Hum. Antibodies 2005, 14:33-55.
13. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
14. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 2005, 23:1117-1125.
15. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010, 9:767-774.
16. Nelson A.L., Reichert J.M. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 2009, 27:331-337.
17. Nelson A.L. Antibody fragments: hope and hype. MAbs 2010, 2:77-83.
18. Arend W.P., Silverblatt F.J. Serum disappearance and catabolism of homologous immunoglobulin fragments in rats. Clin. Exp. Immunol. 1975, 22:502-513.
19. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 1999, 17:780-783.
20. Goel N., Stephens S. Certolizumab pegol. MAbs 2010, 2:137-147.
21. Chames P., Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?. MAbs 2009, 1:539-547.
22. Linke R., Klein A., Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010, 2:129-136.
23. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343-357.
24. Pasquetto M.V., Vecchia L., Covini D., Digilio R., Scotti C. Targeted drug delivery using immunoconjugates: principles and applications. J. Immunother. 2011, 34:611-628.
25. Yang W.P., Green K., Pinz-Sweeney S., Briones A.T., Burton D.R., Barbas C.F. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 1995, 254:392-403.
26. Schier R., McCall A., Adams G.P., Marshall K.W., Merritt H., Yim M., Crawford R.S., Weiner L.M., Marks C., Marks J.D. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 1996, 263:551-567.
27. Wakankar A., Chen Y., Gokarn Y., Jacobson F.S. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011, 3:161-172.
28. Hermanson G.T. Bioconjugate Techniques 1996, Academic Press, San Diego.
29. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., DeBlanc R.L., Gearing R.P., Bovee T.D., Siegall C.B., Francisco J.A., Wahl A.F., Meyer D.L., Senter P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21:778-784.
30. Foyil K.V., Bartlett N.L. Anti-CD30 antibodies for Hodgkin lymphoma. Curr. Hematol. Malig. Rep. 2010, 5:140-147.
31. Rodwell J.D., Alvarez V.L., Lee C., Lopes A.D., Goers J.W., King H.D., Powsner H.J., McKearn T.J. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2632-2636.
32. Qu Z., Sharkey R.M., Hansen H.J., Shih L.B., Govindan S.V., Shen J., Goldenberg D.M., Leung S.O. Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates. J. Immunol. Methods 1998, 213:131-144.
33. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y., Simpson M., Tsai S.P., Dennis M.S., Lu Y., Meng Y.G., Ng C., Yang J., Lee C.C., Duenas E., Gorrell J., Katta V., Kim A., McDorman K., Flagella K., Venook R., Ross S., Spencer S.D., Lee Wong W., Lowman H.B., Vandlen R., Sliwkowski M.X., Scheller R.H., Polakis P., Mallet W. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 2008, 26:925-932.
34. Ducry L., Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem. 2010, 21:5-13.
35. Erickson H.K., Lewis Phillips G.D., Leipold D.D., Provenzano C.A., Mai E., Johnson H.A., Gunter B., Audette C.A., Gupta M., Pinkas J., Tibbitts J. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol. Cancer Ther. 2012, 11:1133-1142.
36. Choudhary S., Mathew M., Verma R.S. Therapeutic potential of anticancer immunotoxins. Drug Discov. Today 2011, 16:495-503.
37. Steiner M., Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 2011, 17:6406-6416.
38. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
39. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
40. Li Z., Yu T., Zhao P., Ma J. Immunotoxins and cancer therapy. Cell. Mol. Immunol. 2005, 2:106-112.
41. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science 1988, 242:423-426.
42. Pastan I., Hassan R., FitzGerald D.J., Kreitman R.J. Immunotoxin treatment of cancer. Annu. Rev. Med. 2007, 58:221-237.
43. Manoukian G., Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin. Biol. Ther. 2009, 9:1445-1451.
44. Strauchen J.A., Breakstone B.A. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am. J. Pathol. 1987, 126:506-512.
45. Sharkey R.M., Goldenberg D.M. Cancer radioimmunotherapy. Immunotherapy 2011, 3:349-370.
46. Palanca-Wessels M.C., Press O.W. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 2010, 116:1126-1133.
47. Sharkey R.M., Burton J., Goldenberg D.M. Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev. Clin. Immunol. 2005, 1:47-62.
48. Murray J.L., Macey D.J., Kasi L.P., Rieger P., Cunningham J., Bhadkamkar V., Zhang H.Z., Schlom J., Rosenblum M.G., Podoloff D.A. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 1994, 73:1057-1066.
49. Sharkey R.M., Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 2005, 46(Suppl. 1):115S-127S.
50. Chari R.V. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug Deliv. Rev. 1998, 31:89-104.
51. Pietersz G.A., Rowland A., Smyth M.J., McKenzie I.F. Chemoimmunoconjugates for the treatment of cancer. Adv. Immunol. 1994, 56:301-387.
52. Senter P.D. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 2009, 13:235-244.
53. Comereski C.R., Peden W.M., Davidson T.J., Warner G.L., Hirth R.S., Frantz J.D. BR96-doxorubicin conjugate (BMS-182248) versus doxorubicin: a comparative toxicity assessment in rats. Toxicol. Pathol. 1994, 22:473-488.
54. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellstrom I., Hellstrom K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261:212-215.
55. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., Young L., Healey D., Onetto N., Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17:478-484.
56. Chari R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41:98-107.
57. Singh Y., Palombo M., Sinko P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 2008, 15:1802-1826.
58. Madden T., Tran H.T., Beck D., Huie R., Newman R.A., Pusztai L., Wright J.J., Abbruzzese J.L. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res. 2000, 6:1293-1301.
59. Ratanatharathorn V., Gad-el-Mawla N., Wilson H.E., Bonnet J.D., Rivkin S.E., Mass R. Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. Cancer Treat. Rep. 1982, 66:1687-1688.
60. Minich S.S. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann. Pharmacother. 2012, 46:377-383.
61. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011, 307:113-118.
62. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., Tan-Chiu E., Krop I.E., Michaelson R.A., Girish S., Amler L., Zheng M., Chu Y.W., Klencke B., O'Shaughnessy J.A. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 2011, 29:398-405.
63. Krop I.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., Girish S., Tibbitts J., Yi J.H., Sliwkowski M.X., Jacobson F., Lutzker S.G., Burris H.A. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 2010, 28:2698-2704.
64. LoRusso P.M., Weiss D., Guardino E., Girish S., Sliwkowski M.X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 2011, 17:6437-6447.
65. Ricart A.D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 2011, 17:6417-6427.
66. Advani A., Coiffier B., Czuczman M.S., Dreyling M., Foran J., Gine E., Gisselbrecht C., Ketterer N., Nasta S., Rohatiner A., Schmidt-Wolf I.G., Schuler M., Sierra J., Smith M.R., Verhoef G., Winter J.N., Boni J., Vandendries E., Shapiro M., Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol. 2010, 28:2085-2093.
67. Teicher B.A., Chari R.V. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 2011, 17:6389-6397.
68. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4607-4612.
69. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
70. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994, 54:3352-3356.
71. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 2010, 21:797-802.
72. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
73. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
74. Greenwald R.B., Conover C.D., Choe Y.H. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit. Rev. Ther. Drug Carrier Syst. 2000, 17:101-161.
75. Bhatt R., de Vries P., Tulinsky J., Bellamy G., Baker B., Singer J.W., Klein P. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem. 2003, 46:190-193.
76. Singer J.W., Bhatt R., Tulinsky J., Buhler K.R., Heasley E., Klein P., de Vries P. Water-soluble poly-(l-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J. Control. Release 2001, 74:243-247.
77. Mitsui I., Kumazawa E., Hirota Y., Aonuma M., Sugimori M., Ohsuki S., Uoto K., Ejima A., Terasawa H., Sato K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res. 1995, 86:776-782.
78. Harada M., Murata J., Sakamura Y., Sakakibara H., Okuno S., Suzuki T. Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats. J. Control. Release 2001, 71:71-86.
79. Etrych T., Sirova M., Starovoytova L., Rihova B., Ulbrich K. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol. Pharm. 2010, 7:1015-1026.
80. Chandran S.S., Nan A., Rosen D.M., Ghandehari H., Denmeade S.R. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol. Cancer Ther. 2007, 6:2928-2937.
81. Caiolfa V.R., Zamai M., Fiorino A., Frigerio E., Pellizzoni C., d'Argy R., Ghiglieri A., Castelli M.G., Farao M., Pesenti E., Gigli M., Angelucci F., Suarato A. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Control. Release 2000, 65:105-119.
82. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., Davis M.E. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006, 12:1606-1614.
83. Davis M.E. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 2009, 61:1189-1192.
84. Shiah J.G., Sun Y., Kopeckova P., Peterson C.M., Straight R.C., Kopecek J. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates. J. Control. Release 2001, 74:249-253.
85. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 2009, 61:1203-1213.
86. Torchilin V.P., Lukyanov A.N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today 2003, 8:259-266.
87. Pasut G., Veronese F.M. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 2011, 161(2):461-472.
88. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10:1451-1458.
89. Wang M.D., Shin D.M., Simons J.W., Nie S. Nanotechnology for targeted cancer therapy. Expert Rev. Anticancer Ther. 2007, 7:833-837.
90. Alexis F., Pridgen E.M., Langer R., Farokhzad O.C. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010, 55-86. Springer-Verlag, Berlin Heidelberg. M. Schar̈fer-Korting (Ed.).
91. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
92. Heath J.R., Davis M.E. Nanotechnology and cancer. Annu. Rev. Med. 2008, 59:251-265.
93. Lasic D.D. Liposomes: From Physics to Applications 1993, Elsevier, Amsterdam.
94. Gabizon A.A. Liposomal anthracyclines. Hematol. Oncol. Clin. North Am. 1994, 8:431-450.
95. Gabizon A., Chisin R., Amselem S., Druckmann S., Cohen R., Goren D., Fromer I., Peretz T., Sulkes A., Barenholz Y. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 1991, 64:1125-1132.
96. Liu D., Hu Q., Song Y.K. Liposome clearance from blood: different animal species have different mechanisms. Biochim. Biophys. Acta 1995, 1240:277-284.
97. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
98. Gabizon A.A. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv. Drug Deliv. Rev. 1995, 16:285-294.
99. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6949-6953.
100. Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987, 223:42-46.
101. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv. Drug Deliv. Rev. 1995, 16:141-155.
102. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:11460-11464.
103. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113:171-199.
104. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252:3582-3586.
105. Woodle M.C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem. Phys. Lipids 1993, 64:249-262.
106. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1991, 1062:77-82.
107. Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3:123-193.
108. Allen T.M. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 1994, 13:285-309.
109. Chonn A., Semple S.C., Cullis P.R. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim. Biophys. Acta 1991, 1070:215-222.
110. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1991, 1070:187-192.
111. Torchilin V.P. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul. 1998, 15:1-19.
112. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
113. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19:424-436.
114. Huang S.K., Stauffer P.R., Hong K., Guo J.W., Phillips T.L., Huang A., Papahadjopoulos D. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 1994, 54:2186-2191.
115. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
116. Boman N.L., Masin D., Mayer L.D., Cullis P.R., Bally M.B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994, 54:2830-2833.
117. Allen T.M., Mehra T., Hansen C., Chin Y.C. Stealth liposomes: an improved sustained release system for 1-beta-d-arabinofuranosylcytosine. Cancer Res. 1992, 52:2431-2439.
118. Kim E.S., Lu C., Khuri F.R., Tonda M., Glisson B.S., Liu D., Jung M., Hong W.K., Herbst R.S. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2001, 34:427-432.
119. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51:691-743.
120. Abra R.M., Hunt C.A. Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim. Biophys. Acta 1981, 666:493-503.
121. Allen T.M., Hansen C., Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 1989, 981:27-35.
122. Moein Moghimi S., Hamad I., Bunger R., Andresen T.L., Jorgensen K., Hunter A.C., Baranji L., Rosivall L., Szebeni J. Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J. Liposome Res. 2006, 16:167-174.
123. Whiteman K.R., Subr V., Ulbrich K., Torchilin V.P. Poly(HPMA)-coated liposomes demonstrate prolonged circulation in mice. J. Liposome Res. 2001, 11:153-164.
124. Torchilin V.P., Levchenko T.S., Whiteman K.R., Yaroslavov A.A., Tsatsakis A.M., Rizos A.K., Michailova E.V., Shtilman M.I. Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 2001, 22:3035-3044.
125. Metselaar J.M., Bruin P., de Boer L.W., de Vringer T., Snel C., Oussoren C., Wauben M.H., Crommelin D.J., Storm G., Hennink W.E. A novel family of l-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug. Chem. 2003, 14:1156-1164.
126. Takeuchi H., Kojima H., Yamamoto H., Kawashima Y. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J. Control. Release 2001, 75:83-91.
127. Torchilin V.P., Khaw B.A., Smirnov V.N., Haber E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 1979, 89:1114-1119.
128. Barbet J., Machy P., Leserman L.D. Monoclonal antibody covalently coupled to liposomes: specific targeting to cells. J. Supramol. Struct. Cell. Biochem. 1981, 16:243-258.
129. Heath T.D., Montgomery J.A., Piper J.R., Papahadjopoulos D. Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma-aspartate. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:1377-1381.
130. Huang A., Kennel S.J., Huang L. Interactions of immunoliposomes with target cells. J. Biol. Chem. 1983, 258:14034-14040.
131. Torchilin V.P. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 1985, 2:65-115.
132. Connor J., Norley N., Huang L. Biodistribution of pH-sensitive immunoliposomes. Biochim. Biophys. Acta 1986, 884:474-481.
133. Torchilin V.P., Klibanov A.L., Huang L., O'Donnell S., Nossiff N.D., Khaw B.A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 1992, 6:2716-2719.
134. Torchilin V.P. Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. Immunomethods 1994, 4:244-258.
135. Torchilin V.P., Narula J., Halpern E., Khaw B.A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta 1996, 1279:75-83.
136. Sawant R.R., Torchilin V.P. Design and synthesis of novel functional lipid-based bioconjugates for drug delivery and other applications. Methods Mol. Biol. 2011, 751:357-378.
137. Torchilin V.P., Levchenko T.S., Lukyanov A.N., Khaw B.A., Klibanov A.L., Rammohan R., Samokhin G.P., Whiteman K.R. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 2001, 1511:397-411.
138. Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Deliv. 2008, 5:1003-1025.
139. Duggan S.T., Keating G.M. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 2011, 71:2531-2558.
140. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., Wirth C., Shalaby R., Kotts C., Wood W.I., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1327-1331.
141. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
142. Park J.W., Hong K., Kirpotin D.B., Meyer O., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 1997, 118:153-160.
143. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., Marks J.D., Papahadjopoulos D., Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 2001, 74:95-113.
144. Shmeeda H., Tzemach D., Mak L., Gabizon A. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J. Control. Release 2009, 136:155-160.
145. Elbayoumi T.A., Torchilin V.P. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:1196-1205.
146. Elbayoumi T.A., Torchilin V.P. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci. 2007, 32:159-168.
147. Elbayoumi T.A., Torchilin V.P. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. Int. J. Pharm. 2008, 357:272-279.
148. Elbayoumi T.A., Torchilin V.P. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol. Pharm. 2009, 6:246-254.
149. ElBayoumi T.A., Torchilin V.P. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res. 2009, 15:1973-1980.
150. Gupta B., Levchenko T.S., Mongayt D.A., Torchilin V.P. Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo. J. Drug Target. 2005, 13:337-343.
151. Cheng W.W., Allen T.M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J. Control. Release 2008, 126:50-58.
152. Allen T.M., Mumbengegwi D.R., Charrois G.J. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin. Cancer Res. 2005, 11:3567-3573.
153. Chen W.C., Completo G.C., Sigal D.S., Crocker P.R., Saven A., Paulson J.C. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 2010, 115:4778-4786.
154. Hatakeyama H., Akita H., Ishida E., Hashimoto K., Kobayashi H., Aoki T., Yasuda J., Obata K., Kikuchi H., Ishida T., Kiwada H., Harashima H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm. 2007, 342:194-200.
155. Wicki A., Rochlitz C., Orleth A., Ritschard R., Albrecht I., Herrmann R., Christofori G., Mamot C. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin. Cancer Res. 2012, 18:454-464.
156. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., Kirpotin D.B., Park J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65:11631-11638.
157. Hussain S., Pluckthun A., Allen T.M., Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther. 2007, 6:3019-3027.
158. Brignole C., Marimpietri D., Gambini C., Allen T.M., Ponzoni M., Pastorino F. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. 2003, 197:199-204.
159. Pastorino F., Brignole C., Marimpietri D., Sapra P., Moase E.H., Allen T.M., Ponzoni M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003, 63:86-92.
160. Etzerodt A., Maniecki M.B., Graversen J.H., Moller H.J., Torchilin V.P., Moestrup S.K. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J. Control. Release 2012, 160(1):72-80.
161. Pan H., Han L., Chen W., Yao M., Lu W. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J. Control. Release 2008, 125:228-235.
162. Moreira J.N., Gaspar R., Allen T.M. Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim. Biophys. Acta 2001, 1515:167-176.
163. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66:6732-6740.
164. Sapra P., Allen T.M. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin. Cancer Res. 2004, 10:2530-2537.
165. Hosokawa S., Tagawa T., Niki H., Hirakawa Y., Nohga K., Nagaike K. Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br. J. Cancer 2003, 89:1545-1551.
166. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2:750-763.
167. Pardridge W.M. shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev. 2007, 59:141-152.
168. Boado R.J. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm. Res. 2007, 24:1772-1787.
169. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
170. Levchenko T.S., Hartner W.C., Verma D.D., Bernstein E.A., Torchilin V.P. ATP-loaded liposomes for targeted treatment in models of myocardial ischemia. Methods Mol. Biol. 2010, 605:361-375.
171. Verma D.D., Levchenko T.S., Bernstein E.A., Mongayt D., Torchilin V.P. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J. Drug Target. 2006, 14:273-280.
172. Sawant R.R., Torchilin V.P. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol. Membr. Biol. 2010, 27:232-246.
173. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 2001, 73:137-172.
174. Torchilin V.P. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 2002, 54:235-252.
175. Torchilin V.P., Rammohan R., Weissig V., Levchenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8786-8791.
176. Gao Z., Lukyanov A.N., Chakilam A.R., Torchilin V.P. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J. Drug Target. 2003, 11:87-92.
177. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6039-6044.
178. Roby A., Erdogan S., Torchilin V.P. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur. J. Pharm. Biopharm. 2006, 62:235-240.
179. Roby A., Erdogan S., Torchilin V.P. Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biol. Ther. 2007, 6:1136-1142.
180. Skidan I., Dholakia P., Torchilin V. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. J. Drug Target. 2008, 16:486-493.
181. Jin C., Qian N., Zhao W., Yang W., Bai L., Wu H., Wang M., Song W., Dou K. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')2 for hepatocellular carcinoma. Biomacromolecules 2010, 11:2422-2431.
182. Li W., Zhao H., Qian W., Li H., Zhang L., Ye Z., Zhang G., Xia M., Li J., Gao J., Li B., Kou G., Dai J., Wang H., Guo Y. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 2012, 21:5349-5362.
183. Groneberg D.A., Giersig M., Welte T., Pison U. Nanoparticle-based diagnosis and therapy. Curr. Drug Targets 2006, 7:643-648.
184. Torchilin V.P. Lipid-core micelles for targeted drug delivery. Curr. Drug Deliv. 2005, 2:319-327.
185. Sawant R., Sawant R., Gultepe E., Nagesha D., Papahadjopoulos-Sternberg B., Sridhar S., Torchilin V. Nanosized cancer cell-targeted polymeric immunomicelles loaded with superparamagnetic iron oxide nanoparticles. J. Nanopart. Res. 2009, 11:1777-1785.
186. Papagiannaros A., Upponi J., Hartner W., Mongayt D., Levchenko T., Torchilin V. Quantum dot loaded immunomicelles for tumor imaging. BMC Med. Imaging 2010, 10:22.
187. Nurunnabi M., Cho K.J., Choi J.S., Huh K.M., Lee Y.K. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials 2010, 31:5436-5444.
188. Felber A.E., Castagner B., Elsabahy M., Deleavey G.F., Damha M.J., Leroux J.C. siRNA nanocarriers based on methacrylic acid copolymers. J. Control. Release 2011, 152:159-167.
189. Palanca-Wessels M.C., Convertine A.J., Cutler-Strom R., Booth G.C., Lee F., Berguig G.Y., Stayton P.S., Press O.W. Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol. Ther. 2011, 19:1529-1537.
190. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9:E128-E147.
191. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 2006, 58:1532-1555.
192. Basel M.T., Shrestha T.B., Troyer D.L., Bossmann S.H. Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release. ACS Nano 2011, 5:2162-2175.
193. Wike-Hooley J.L., Haveman J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 1984, 2:343-366.
194. Kallinowski F., Schlenger K.H., Runkel S., Kloes M., Stohrer M., Okunieff P., Vaupel P. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res. 1989, 49:3759-3764.
195. Gerweck L.E., Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 1996, 56:1194-1198.
196. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 2003, 55:199-215.
197. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60:1197-1201.
198. Zhu L., Huo Z., Wang L., Tong X., Xiao Y., Ni K. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int. J. Pharm. 2009, 370:136-143.
199. Alexiou C., Arnold W., Klein R.J., Parak F.G., Hulin P., Bergemann C., Erhardt W., Wagenpfeil S., Lubbe A.S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000, 60:6641-6648.
200. Schroeder A., Honen R., Turjeman K., Gabizon A., Kost J., Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J. Control. Release 2009, 137:63-68.
201. Toncheva V., Schacht E., Ng S.Y., Barr J., Heller J. Use of block copolymers of poly(ortho esters) and poly (ethylene glycol) micellar carriers as potential tumour targeting systems. J. Drug Target. 2003, 11:345-353.
202. Shin J., Shum P., Thompson D.H. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control. Release 2003, 91:187-200.
203. Gumusderelioglu M., Kesgin D. Release kinetics of bovine serum albumin from pH-sensitive poly(vinyl ether) based hydrogels. Int. J. Pharm. 2005, 288:273-279.
204. Kratz F., Beyer U., Roth T., Schutte M.T., Unold A., Fiebig H.H., Unger C. Albumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in vitro efficacy. Arch. Pharm. 1998, 331:47-53.
205. Beyer U., Roth T., Schumacher P., Maier G., Unold A., Frahm A.W., Fiebig H.H., Unger C., Kratz F. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil. J. Med. Chem. 1998, 41:2701-2708.
206. Shen W.C., Ryser H.J. cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 1981, 102:1048-1054.
207. Ogden J.R., Leung K., Kunda S.A., Telander M.W., Avner B.P., Liao S.K., Thurman G.B., Oldham R.K. Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity. Mol. Biother. 1989, 1:170-174.
208. Gillies E.R., Jonsson T.B., Frechet J.M. Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. J. Am. Chem. Soc. 2004, 126:11936-11943.
209. Gillies E.R., Frechet J.M. pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug. Chem. 2005, 16:361-368.
210. Heffernan M.J., Murthy N. Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle. Bioconjug. Chem. 2005, 16:1340-1342.
211. Oishi M., Nagasaki Y., Itaka K., Nishiyama N., Kataoka K. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 2005, 127:1624-1625.
212. Biswas S., Dodwadkar N.S., Sawant R.R., Torchilin V.P. Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization. Bioconjug. Chem. 2011, 22:2005-2013.
213. Hallbrink M., Floren A., Elmquist A., Pooga M., Bartfai T., Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 2001, 1515:101-109.
214. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
215. Tachibana R., Harashima H., Shono M., Azumano M., Niwa M., Futaki S., Kiwada H. Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking. Biochem. Biophys. Res. Commun. 1998, 251:538-544.
216. Sawant R.M., Hurley J.P., Salmaso S., Kale A., Tolcheva E., Levchenko T.S., Torchilin V.P. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 2006, 17:943-949.
217. Koren E., Apte A., Jani A., Torchilin V.P. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J. Control. Release 2011, 160(2):264-273.
218. Kale A.A., Torchilin V.P. "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J. Liposome Res. 2007, 17:197-203.
219. Kale A.A., Torchilin V.P. Environment-responsive multifunctional liposomes. Methods Mol. Biol. 2010, 605:213-242.
220. Zhu L., Kate P., Torchilin V.P. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6:3491-3498.
221. Kono K., Yoshino K., Takagishi T. Effect of poly(ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymer-modified liposomes. J. Control. Release 2002, 80:321-332.
222. Kono K. Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 2001, 53:307-319.
223. Schild H.G. Poly (N-isopropylacrylamide) - experiment, theory and application. Prog. Polym. Sci. 1992, 17:163-249.
224. Elbayoumi T.A., Pabba S., Roby A., Torchilin V.P. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 2007, 17:1-14.